How Many Calories to Eat on GLP-1 Drugs: Why the Answer Is Not 'As Few as Possible'

The counter-intuitive problem: GLP-1 drugs can suppress appetite too effectively

GLP-1 receptor agonists work in part by activating satiety signals in the hypothalamus. For most patients, this translates to significantly reduced hunger — which is the intended therapeutic effect.

For some patients, particularly at higher doses or during rapid escalation, appetite suppression becomes extreme. Patients report eating 500–800 calories per day during periods of nausea and appetite loss, sometimes for weeks.

At these intake levels, the body does not selectively lose fat. It catabolises lean mass aggressively, causing rapid muscle loss, weakness, fatigue, and a suppressed resting metabolic rate. This is the opposite of a good therapeutic outcome.

The question is not "how little can I eat on GLP-1?" but "what is the right minimum calorie floor for my size and goals?"

Why very-low-calorie intake on GLP-1 is harmful

1. Lean mass loss accelerates. Below roughly 1,000–1,200 calories, the body cannot maintain adequate protein synthesis even with high protein intake. Muscle is catabolised for gluconeogenesis. This is why very-low-calorie diet (VLCD) protocols — used in medical supervision — require specific monitoring and are time-limited.

2. Metabolic adaptation. Prolonged severe caloric restriction causes adaptive thermogenesis: the resting metabolic rate drops disproportionately to match intake. This makes long-term weight maintenance harder and increases regain risk when the drug is stopped.

3. Micronutrient deficiency. At 600 calories per day, meeting any micronutrient reference daily intake is impossible. Deficiencies accumulate — some with irreversible consequences (neuropathy from B12, bone density from calcium/D).

4. Fatigue and functional decline. Extreme restriction is cognitively and physically debilitating. Patients can't exercise effectively, which undermines the lean mass preservation half of the protocol.

The evidence-based calorie range for GLP-1 patients

Clinical obesity nutrition guidelines and the study protocols from major GLP-1 trials used these calorie targets:

Minimum floor: 1,200 kcal/day for women; 1,400 kcal/day for men. These are the floors below which nutritional adequacy cannot be reliably maintained and clinical monitoring is required.

Working target range: 1,200–1,600 kcal/day is appropriate for most GLP-1 patients during active weight loss. This creates a meaningful deficit (most adults maintain weight at 1,800–2,400 kcal) while remaining nutritionally adequate with deliberate food choices.

Activity-adjusted: Patients doing regular resistance training (3+ sessions/week) should be at the upper end of this range or above — 1,600–1,800 kcal/day — to support muscle protein synthesis and training recovery.

How to know if you're eating too little

Signs that caloric intake has dropped too low:

• Extreme fatigue disproportionate to weight lost
• Muscle weakness — difficulty with stairs, carrying loads, functional tasks you could do before
• Hair loss (telogen effluvium can be worsened by extreme restriction, not just weight loss alone)
• Dizziness and lightheadedness standing
• Cold intolerance (hypothyroid-like symptoms from low T3 in severe restriction)
• Loss of interest in everything, not just food

If these occur, caloric intake needs to increase — ideally by adding protein and fat-rich foods that are calorically dense relative to volume (nut butters, full-fat dairy, eggs, avocado).

How to eat enough when GLP-1 has eliminated appetite

GLP-1-induced appetite suppression makes eating a deliberate act rather than an automatic one. Strategies:

Eat on a schedule, not on hunger. If waiting for hunger signals that no longer reliably arrive, patients will undereat. Set eating times (e.g., 8 am, 12:30 pm, 5:30 pm) and eat at them regardless of appetite.

Prioritise calorie density per bite. With limited volume capacity, calories-per-bite matters. Watery, high-volume foods (salads, broth-based soups as a staple) can't sustain adequate intake. Include:

• Full-fat Greek yogurt (170 kcal per 200 g)
• Nut butters (200 kcal per 2 tbsp)
• Avocado (230 kcal per medium fruit)
• Olive oil on everything
• Eggs (70 kcal each)

Track for the first 4–8 weeks. Not obsessively, but accurately enough to know if intake is in the therapeutic range. Many patients are surprised to discover they're eating 800 calories when they thought they were eating 1,200.

Eat protein first, add fat. High-protein foods combined with fat are both nutritionally valuable and calorie-dense. A meal of 100 g salmon + avocado + Greek yogurt provides ~700 kcal in a small volume.

The relationship between calories and GLP-1 efficacy

Some patients believe eating less will accelerate weight loss. The evidence does not support this beyond a point.

GLP-1 drugs create weight loss primarily through the appetite suppression and increased satiety they produce. The drug does the caloric restriction work. Patients who stack additional restriction on top typically:

1. Lose more lean mass, not more fat
2. Develop worse side effects (nausea is exacerbated by empty stomach)
3. Experience more fatigue
4. Hit harder plateaus when the drug's suppression effect moderates

The goal is eating at a caloric level that produces a steady 0.5–1 kg/week fat loss (a ~500–750 kcal/day deficit), with lean mass preserved through protein and exercise. Not maximum suppression.

How to calculate a rough personal target

A rough maintenance calorie estimate (TDEE) using the Mifflin-St Jeor equation:

Women: (10 × weight in kg) + (6.25 × height in cm) - (5 × age) - 161 Men: (10 × weight in kg) + (6.25 × height in cm) - (5 × age) + 5

Multiply by an activity factor:

• Sedentary: × 1.2
• Light activity (1–3 days/week): × 1.375
• Moderate (3–5 days/week): × 1.55

Then subtract 500–750 kcal to create a weight-loss deficit. The result should not fall below 1,200 kcal (women) or 1,400 kcal (men) — if the math takes you below those floors, use the floors.

For most GLP-1 patients, this calculation is academic because the drug is already creating the deficit. The more useful application is checking that actual intake is not falling below the floor.

Summary

GLP-1-induced appetite suppression can push caloric intake below safe and effective levels. The floor for most patients is 1,200–1,500 kcal/day, with protein prioritised at every meal. Eating too little accelerates lean mass loss, causes micronutrient deficiency, and impairs training — the opposite of a good weight-loss outcome. Structured meal timing, calorie-dense foods, and short-term tracking are the practical tools for staying in the therapeutic range.

This article is queued for review by a registered dietitian. It should not be used as personal nutrition advice.